article thumbnail

GPhC November pass rate drops again to 2022 levels

The Pharmacist

This brings the pass rates back down almost to November 2022 levels of 56%, following a 10% rise to 66% in November 2023. And it comes as summer pass rates have seen a steady decline […] The post GPhC November pass rate drops again to 2022 levels appeared first on The Pharmacist.

Diabetes 121
article thumbnail

More than 50 Access Scheme pharmacies have closed since 2022, NPA claims

The Pharmacist

This represents 4% of the 1,444 pharmacies eligible to claim funding under the scheme set up to 'capture the pharmacies that are most important for patient access, those […] The post More than 50 Access Scheme pharmacies have closed since 2022, NPA claims appeared first on The Pharmacist.

134
134
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Opinion: Herding cats: It’s past time to include pets in disease surveillance

STAT

Since 2022, more than 100 domesticated cats in the United States have had confirmed infections — some house pets, some barn cats, some feral — with high mortality, although mortality data remain undocumented on federal sites.

359
359
article thumbnail

U.S. government spent more on health care in 2022 than six countries with universal health care combined

STAT

trillion in federal and state health care expenditures in 2022 — about 41% of the nearly $4.5 American taxpayers footed the bill for at least $1.8 trillion in both public and private health care spending the U.S. recorded last year, according to the annual report released last week by the Centers for Medicare and Medicaid Services.

364
364
article thumbnail

The 2022 PharmaVoice 100

PharmaVoice

From standout executives to R&D pioneers — this year’s class of honorees is defining the next era of leadership.

344
344
article thumbnail

STAT+: FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system

STAT

billion in revenue by dispensing medicines to treat cancer, HIV, heart disease and other serious illnesses at prices that exceeded their estimated acquisition costs between 2017 and 2022. Specifically, the companies were able to generate more than $7.3 Continue to STAT+ to read the full story…

article thumbnail

STAT+: The prices of 8 drugs were hiked without proof of new benefits, costing the U.S. $1.2 billion in 2022, report finds

STAT

During 2022, drugmakers substantially raised prices on eight widely used medicines without any new clinical evidence to justify the increases, leading patients and health insurers in the U.S. to spend an additional $1.2 billion last year, according to a new report.